VTGN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

VT

Volume

487.38K

Next Earnings

November 12th

Loading chart

VT

VTGNVistagen Therapeutics, Inc. Common Stock

VTGN

Pay with—

Available Balance0.00

VT

Mkt Cap

$9.5M

Volume

487.38K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmKuehn Law is investigating whether officers and directors of Vistagen Therapeutics breached fiduciary duties by misrepresenting or failing to disclose risks in their Social Anxiety Disorder clinical trials. The firm alleges insiders downplayed known issues with public speaking challenge endpoints, including elevated placebo responses and site variability, while promoting the PALISADE-3 trial as likely to succeed. The law firm is seeking shareholders who purchased stock prior to April 1, 2024.Benzinga · Jun 1, 2026

VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGNA securities class action lawsuit has been filed against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) alleging that defendants made materially false and misleading statements regarding the company's drug fasedienol and its Phase 3 PALISADE-3 clinical trial. Investors who purchased VTGN stock between April 1, 2024 and December 16, 2025 may be eligible for compensation. The deadline to serve as lead plaintiff is March 16, 2026.GlobeNewswire Inc. · Mar 14, 2026

Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Vistagen Therapeutics for alleged securities fraud, claiming the company made materially false and misleading statements about its fasedienol drug candidate and the PALISADE-3 clinical trial while concealing adverse data. Investors who purchased Vistagen securities between April 1, 2024 and December 16, 2025 may be eligible to join the case, with a lead plaintiff deadline of March 16, 2026.GlobeNewswire Inc. · Mar 12, 2026

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm is seeking investors who purchased Vistagen Therapeutics securities between April 1, 2024 and December 16, 2025 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its fasedienol drug candidate's Phase 3 success potential in the PALISADE-2 trial and downplayed clinical failure risks, resulting in investor losses.GlobeNewswire Inc. · Mar 9, 2026

VTGN DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGNRosen Law Firm is notifying investors in Vistagen Therapeutics who purchased stock between April 1, 2024 and December 16, 2025 of a March 16, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Vistagen made false and misleading statements about its drug fasedienol and the PALISADE-3 clinical trial, providing overly positive assertions while concealing material adverse facts about the Phase 3 trial.GlobeNewswire Inc. · Mar 7, 2026

Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Vistagen Therapeutics for alleged securities fraud. The complaint alleges that the company made materially false and misleading statements regarding its fasedienol drug candidate and the Phase 3 PALISADE-3 trial for social anxiety disorder treatment, while concealing adverse clinical data. Investors who purchased Vistagen securities between April 1, 2024 and December 16, 2025 may be eligible to join the case.GlobeNewswire Inc. · Mar 5, 2026

VTGN DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGNA securities class action lawsuit has been filed against Vistagen Therapeutics regarding alleged material misstatements and omissions concerning its fasedienol drug trial (PALISADE-3) for social anxiety disorder. The company allegedly made positive assertions about the drug's future success while concealing adverse facts about the Phase 3 trial. Investors who purchased stock between April 1, 2024 and December 16, 2025 may be eligible for compensation, with a March 16, 2026 deadline to serve as lead plaintiff.GlobeNewswire Inc. · Mar 5, 2026

Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff DeadlineA class action lawsuit has been filed against Vistagen Therapeutics for allegedly providing misleading statements regarding its Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder. The trial failed to meet its primary endpoint, causing Vistagen's stock to plummet over 80% from $4.36 to $0.86 per share on December 17, 2025. Investors who purchased shares between April 1, 2024 and December 16, 2025 have until March 16, 2026 to apply as lead plaintiff.GlobeNewswire Inc. · Mar 5, 2026

VTGN DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGNA securities class action lawsuit has been filed against Vistagen Therapeutics regarding alleged material misstatements about its fasedienol drug development for social anxiety disorder. Investors who purchased VTGN stock between April 1, 2024 and December 16, 2025 may be eligible for compensation. The lead plaintiff deadline is March 16, 2026.GlobeNewswire Inc. · Mar 2, 2026

הודעה על מועד אחרון לתביעה נגד VTGN: רוזן, יועץ מהימן למשקיעים, מעודד את משקיעי Vistagen Therapeutics, Inc להשיג ייעוץ משפטי לפני המועד האחרון החשוב בתביעה ייצוגית בניירות ערך – VTGNRosen Law Firm announces a March 16, 2026 deadline for investors to join a securities class action lawsuit against Vistagen Therapeutics, Inc. (VTGN). The lawsuit alleges that company defendants made misleading positive statements about the fasedienol drug trial (PALISADE-3) for acute social anxiety disorder treatment while concealing material negative facts, causing shareholders to purchase stock at artificially inflated prices.GlobeNewswire Inc. · Mar 2, 2026

to start trading

VT

VTGNVistagen Therapeutics, Inc. Common Stock

VTGN

Pay with—

Available Balance0.00

Your PositionYou don't own any VTGN yet.

Related Tickers

Earnings